Michał Nowicki

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency

Paweł Płudowski, Elżbieta Karczmarewicz, Milan Bayer et al. · Endokrynologia Polska · 2013 · 517 citations · Full text

Reduced Urinary Excretion of Nitric Oxide Metabolites and Increased Plasma Levels of Asymmetric Dimethylarginine in Men with Essential Hypertension

Andrzej Surdacki, Michał Nowicki, Joerg Sandmann et al. · Journal of Cardiovascular Pharmacology · 1999 · 428 citations

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko et al. · Nephrology Dialysis Transplantation · 2020 · 180 citations · Full text

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

Michał Nowicki, Ivan Rychlík, Hermann Haller et al. · International Journal of Clinical Practice · 2011 · 136 citations